Q linea AB
STO:QLINEA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Q linea AB
Long-Term Investments
Q linea AB
Long-Term Investments Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Long-Term Investments | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Q linea AB
STO:QLINEA
|
Long-Term Investments
kr2.2m
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-40%
|
CAGR 10-Years
N/A
|
|
|
Elekta AB (publ)
STO:EKTA B
|
Long-Term Investments
kr732m
|
CAGR 3-Years
0%
|
CAGR 5-Years
6%
|
CAGR 10-Years
N/A
|
|
|
CellaVision AB
STO:CEVI
|
Long-Term Investments
kr2.5m
|
CAGR 3-Years
-22%
|
CAGR 5-Years
-35%
|
CAGR 10-Years
8%
|
|
|
Getinge AB
STO:GETI B
|
Long-Term Investments
kr67m
|
CAGR 3-Years
4%
|
CAGR 5-Years
-46%
|
CAGR 10-Years
N/A
|
|
|
Arjo AB (publ)
STO:ARJO B
|
Long-Term Investments
kr739m
|
CAGR 3-Years
78%
|
CAGR 5-Years
5%
|
CAGR 10-Years
N/A
|
|
|
S
|
Stille AB
STO:STIL
|
Long-Term Investments
kr287k
|
CAGR 3-Years
-21%
|
CAGR 5-Years
-20%
|
CAGR 10-Years
-26%
|
|
Q linea AB
Glance View
Q-linea AB operates as a holding company. The company is headquartered in Uppsala, Uppsala. The company went IPO on 2018-12-07. The firm develops and manufactures in-vitro diagnostic (IVD) solutions for infectious diseases. The firm's core product candidate is ASTar, a fully-automated instrument for Antibiotic Susceptibility Testing (AST). The company measures bacteria's antimicrobial susceptibility using the disposables developed by the Company. The company is able to provide a susceptibility profile within three to six hours directly from a positive blood culture, which enables early administration of antibiotics specifically targeting the disease-causing pathogen. Its main application is the identification of sepsis in hospital patients and the product is aimed primarily at hospital laboratories.
See Also
What is Q linea AB's Long-Term Investments?
Long-Term Investments
2.2m
SEK
Based on the financial report for Dec 31, 2025, Q linea AB's Long-Term Investments amounts to 2.2m SEK.
What is Q linea AB's Long-Term Investments growth rate?
Long-Term Investments CAGR 5Y
-40%
Over the last year, the Long-Term Investments growth was -46%. The average annual Long-Term Investments growth rates for Q linea AB have been -10% over the past three years , -40% over the past five years .
